We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You fudging moron the ceo was on the programme it came out his mouth! Fu chin troll!
Guys, let's keep this real. The ONLY informational that is factual is that coming from company RNSs. Not from some Good Morning Britain TV chat show.
£163k buy?
Wasn’t mentioned but all will be aiming to produce one, that’s the game changer they all want
Did you watch the interview on good morning Britain today? In thst not yesterday's video. Keep up
No way did he mention in that video that avct will be developing an antibody test for covid-19.
this will also be a less intrusive test using just saliva have you seen the process for other tests? Quite a gruesome experience esp if your a child
Yes but if they are planning on testing people in their cars like Germany did are you really going to have people waiting around for 45 minutes your concern is valid to a point however a quicker more accurate test will always be whats required its an upgrade to the one your talking about and they will also be developing an antibody test which will show who's already had it to! And it'll be available in a matter kfweks the ceo said in a video yesterday
I don't think it matters who makes what rapid tests. The world will have billions that need testing and one producer won't be able to produce enough for one country or one market.
I am sure investors will be rewarded by many companies if they are successful with quick non-invasive techniques.
I'm still upping my research as new information comes to hand. I am a shareholder, but I do like to air my concesns/doubts in public, to encourage meaningful debate. Unlike your type, who only wants to hear good news stories.
My understanding of the ceph test is that its for use by medical staff? The machines will be in hospitals. It isn't for use by consumers as far as I'm aware.
Somebody please correct me if I've got that wrong.
I think I can wait 45 minutes in my living room for a reliable test result. But my major concern is that this rival rapid test starts to ship starting this week, in the huge USA market, f the Bloomberg article is accurate.
The Ceph test takes 45 minutes. This one should take 10 minutes and will be distributed to a mass market. There's already multiple tests but eventually the best will dominate as the standard expected and probably formally required you'd think surely. We won't have long to find out ??
So, the big question is, will DHR's Cepheid unit steal a march on AVCT in the point-of-care rapid test market for covid-19, or is there room for both, especially on a global basis?
https://www.bloomberg.com/news/articles/2020-03-21/fda-approves-first-bedside-covid-19-test-by-cepheid
Summary
The math on the COVID-19 epidemiological exponential curve is relentless. Once "community spread" begins, stay-at-home orders become necessary. Later on, mass screening, contact tracing, and selective quarantine may be key.
U.S. states were slow in getting up to speed on COVID-19 testing, but now new entrants to the COVID-19 testing market are emerging.
The U.S. F.D.A. [USFDA] has begun to grant competitors (many of whom have existing testing platforms in place) the flexibility they need to accelerate the scale-up of COVID-19 testing.
The USFDA has now authorized the 50 states to play a leading role in COVID-19 testing at the state level.
Investors should do their own diligence. The purpose of this article is to discuss the "state of the nation" regarding COVID-19 testing--not to opine on the investment prospects of any particular company.
Market-traded companies, such as Abbott Laboratories (NYSE:ABT), Danaher Corporation (NYSE:DHR), and Thermo Fisher Scientific (TMO), may have an important role to play in helping the U.S. to survive the COVID-19 (aka coronavirus) crisis.
Emergency Use Authorization (EUA) allows USFDA to facilitate the use of medical countermeasures, such as COVID-19 testing, during public health emergencies. USFDA has already granted EUAs to ABT, DHR, TMO, and the other market-traded companies identified later in this article, which may serve to expedite the rollout of new COVID-19 testing methodologies via their existing platforms, thereby helping to remove an obstacle to an effective U.S. response to the COVID-19 crisis.